See AZAFAROS B.V.’s activity on LinkedIn
Summary
BREAKING NEWS: AZAFAROS B.V. has secured 132M in oversubscribed Series B financing which will advance the companys lead asset, nizubaglustat, into Phase 3 clinical trials. The financial round was led by JEITO Capital, co-led by Forbion Growth, and with additional participation from Seroba., Pictet Group and existing investors Forbion Ventures, Schroders Capital and BGV (BioGeneration Ventures). Two Phase 3 studies investigating nizubaglustat, a first-in-class dual acting drug candidate in Niemann-Pick Type C (NPC) disease and GM1/GM2 gangliosidoses, will begin later this year. Being able to attract leading life sciences investors to join our existing, strong group of specialist investors is a testament to the impressive accomplishments of the team and the large unmet medical need that currently exists for patients with these hugely debilitating neurological diseases. Read the full story here: https://lnkd.in/eW_YxS_k #investors, #JeitoCapital, #Forbiongrowth, #Seroba, #Pictet, #Forbionventures, #SchrodersCapital, #BioGenerationVentures, #investment, #rarediseases, #GM1, #GM2, #NPC
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
